权益分类	功能权益	普通用户	{{item.name}}会员
{{category.name}}	{{benefitItem.name}}

Dissecting How Xenobiotics Act as Adjuvants for Oral Allergic Sensitization

剖析异生素如何作为口腔过敏致敏佐剂

基本信息

批准号：
10272937
负责人：
Andrew Wang
金额：
$ 56.46万
依托单位：
YALE UNIVERSITY
依托单位国家：
美国
项目类别：
财政年份：
2021
资助国家：
美国
起止时间：
2021-05-24 至 2026-04-30
项目状态：
未结题

来源：
https://reporter.nih.gov/project-details/10272937
关键词：
Acetaminophen Adjuvant Affect Allergic Allergic Disease American Analgesic and Antipyretic Analgesics Antigens Cell Nucleus Cells Chemical Structure Chemicals Child Cholera Toxin Cysteine Data Dendritic Cells Development Dissection Dose Drug usage Environment Environmental Exposure Epithelial Cells Erythroid Etiology Exposure to Fatty acid glycerol esters Food Food Hypersensitivity Food Preservatives Genetic Health Policy High Prevalence Human Hydroquinones Hypersensitivity Ibuprofen Immune response Incidence Ingestion Intestines Knock-out Lead Link Mediating Medicine Modeling Modernization Mus Non-Steroidal Anti-Inflammatory Agents Nuclear Oral Ovalbumin PTGS2 gene Pathway interactions Pharmaceutical Preparations Pharmacology Predisposition Prevalence Process Production Property Public Health Role Severities Signal Transduction Source Specificity Testing Time Work Xenobiotics adduct allergic response dosage food antigen food consumption gut microbiome intestinal epithelium man microbiota novel novel therapeutics nuclear factor-erythroid 2 oral tolerance receptor sensor urban setting

项目摘要

PROJECT SUMMARY Food allergies have been increasing at an exponential rate since 1960 for unknown reasons. We hypothesized that modern xenobiotics that were widely introduced into the modern environment may be acting as allergic adjuvants to break oral tolerance and cause allergy. This proposal will explore how certain non-steroidal anti- inflammatory drugs (NSAIDs) are sufficient for oral allergic sensitization. The proposal will test the overarching hypothesis that adjuvant NSAIDs are activators of the xenobiotic sensor, Nuclear factor erythroid 2-related factor 2 (NRF2), in intestinal epithelial cells, which release IL33 to initiate the allergic response to coincident food antigen. We will use a combination of genetic, pharmacologic, and mass spectroscopic approaches to rigorously test this hypothesis. If confirmed, our work has major implications for why allergies are increasing and could lead to new public health policies and novel therapies for the management of allergic diseases.

项目总结自1960年以来，由于未知原因，食物过敏一直在以指数级的速度增加。我们假设被广泛引入现代环境中的现代异生物质可能会起到过敏的作用打破口服耐受性和引起过敏的佐剂。这项提案将探索某些非类固醇抗肿瘤药物如何炎症药物(非甾体类抗炎药)足以引起口服过敏反应。这项提案将考验最重要的假设佐剂非类固醇抗炎药是异种生物传感器的激活剂，核因子红系2相关肠上皮细胞中的因子2(NRF2)，释放IL33以启动对符合的过敏反应食物抗原。我们将结合使用遗传学、药理学和质谱学方法来严格检验这一假设。如果得到证实，我们的工作对过敏症增加的原因有重大影响并可能导致新的公共卫生政策和管理过敏性疾病的新疗法。